Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Prosopagnosia01:24

Prosopagnosia

1.3K
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
1.3K
Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

110
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

My experience of person-centered and personalized care in early-stage primary progressive aphasia.

Dementia (London, England)·2024
Same author

My experience of living with nonfluent/agrammatic variant primary progressive aphasia: Challenges, compensatory strategies and adaptations.

International journal of language & communication disorders·2022
Same author

Development of a Palliative Care Approach for Primary Progressive Aphasia: My Experience as a Person Living With This Rare Disorder.

Journal of palliative care·2021
Same author

My experience of living with nonfluent/agrammatic variant primary progressive aphasia: Adaptations and strategies to improve quality of life.

Dementia (London, England)·2020
Same author

Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model.

Laboratory investigation; a journal of technical methods and pathology·2013
Same author

A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice.

Molecular therapy : the journal of the American Society of Gene Therapy·2012

Related Experiment Video

Updated: May 2, 2026

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

37.6K

Adaptation to Early-Stage Nonfluent/Agrammatic Variant Primary Progressive Aphasia: A First-Person Account.

Joanne T Douglas1

  • 1Volunteer, Department of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, The University of Alabama at Birmingham, Birmingham, AL, USA joanne.t.douglas@gmail.com.

American Journal of Alzheimer'S Disease and Other Dementias
|February 26, 2014
PubMed
Summary

Primary progressive aphasia (PPA) is a young-onset neurodegenerative disorder. This report details strategies to enhance the quality of life for individuals with early-stage PPA-G, focusing on palliative care.

Keywords:
adaptationfrontotemporal degenerationnonfluent/agrammatic variant primary progressive aphasiapalliative care

More Related Videos

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
10:15

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia

Published on: July 2, 2013

17.4K
Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia
08:48

Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia

Published on: May 6, 2016

12.1K

Related Experiment Videos

Last Updated: May 2, 2026

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping
13:12

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

Published on: August 12, 2019

37.6K
Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
10:15

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia

Published on: July 2, 2013

17.4K
Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia
08:48

Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia

Published on: May 6, 2016

12.1K

Area of Science:

  • Neurology
  • Linguistics
  • Gerontology

Background:

  • Primary progressive aphasia (PPA) is a neurodegenerative condition affecting young adults, marked by progressive language decline.
  • The nonfluent/agrammatic variant (PPA-G) presents with agrammatism and halting speech.
  • Currently, no cure or disease-modifying treatments exist for PPA, necessitating palliative care.

Purpose of the Study:

  • To describe strategies for improving the quality of life in early-stage PPA-G.
  • To address the lack of published information on supportive care for PPA patients.

Main Methods:

  • The report is based on personal experience within a multidisciplinary medical team setting.
  • Focus on practical adaptations and strategies for early-stage PPA-G.

Main Results:

  • Identified a range of strategies and adaptations to improve quality of life.
  • Emphasized the importance of early intervention for maximizing benefits.

Conclusions:

  • Meaningful improvements in quality of life are achievable for individuals with early-stage PPA-G.
  • Further research and dissemination of palliative care strategies are needed.